PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565658
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565658
Infectious Diseases Molecular Diagnostics Market size was valued at USD 37,094.32 Million in 2023, expanding at a CAGR of 4.30% from 2024 to 2032.
The Infectious Diseases Molecular Diagnostics market is a rapidly expanding sector driven by the increasing prevalence of infectious diseases, technological advancements in molecular diagnostics, and the need for precise, fast, and reliable diagnostic tools. Molecular diagnostics offer high sensitivity and specificity, allowing for early detection and monitoring of diseases caused by bacteria, viruses, fungi, and parasites. Key market drivers include the rise in healthcare spending, the growing burden of infectious diseases like COVID-19, HIV, and tuberculosis, and the demand for point-of-care testing solutions. As a result, companies are focusing on developing innovative diagnostic platforms, leading to enhanced market growth across regions, with North America and Europe being major contributors.
Infectious Diseases Molecular Diagnostics Market- Market Dynamics
Rising Prevalence of Infectious Diseases Drives the Need for the Infectious Diseases Molecular Diagnostics Market
The rising prevalence of infectious diseases, including viral, bacterial, fungal, and parasitic infections, has significantly increased the demand for effective diagnostic solutions. Infectious diseases pose a growing global health concern, particularly with the emergence of new pathogens and the re-emergence of previously controlled diseases. According to the National Institute of Health (NIH), Infectious diseases remain one of the leading causes of morbidity and mortality around the world accounting for more than 52 million (33%) annual deaths worldwide. Half of the world's population remains at risk of emerging and re-emerging infectious diseases. The recent figures indicate an estimated 14 million global deaths in children less than 5 years of age, 70% of which resulted from vaccine-preventable diseases and 99% reported in developing countries. This has driven the need for advanced molecular diagnostics, which provide rapid, accurate, and sensitive detection of pathogens at a molecular level. The ability to identify infectious agents early on allows for timely intervention, aiding in disease management, reducing transmission rates, and improving patient outcomes. Consequently, the increasing burden of infectious diseases is a key factor propelling the growth of the infectious diseases molecular diagnostics market.
Infectious Diseases Molecular Diagnostics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.30% over the forecast period (2024-2032)
Based on test type segmentation, Laboratory-based Tests were predicted to show maximum market share in the year 2023
Based on application segmentation, Viral Infections was the leading type in 2023
Based on Product & Service segmentation, Reagents & Kits was the leading type in 2023
Based on technology segmentation, Polymerase Chain Reaction (PCR) was the leading type in 2023
Based on end-user segmentation, Hospitals & Diagnostic Laboratories was the leading type in 2023
On the basis of region, Asia Pacific was the leading revenue generator in 2023
The Global Infectious Diseases Molecular Diagnostics Market is segmented on the basis of Test Type, Application, Product & Services, Technology, End User, and Region.
The market is divided into seven categories based on technology: Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), DNA Microarray, Hybridization-based Assays, CRISPR Diagnostics, and Others (Sanger Sequencing, Multiplex PCR, etc.). PCR is highly accurate in detecting even small amounts of DNA or RNA from pathogens, making it ideal for diagnosing infectious diseases. This precision leads to early and accurate detection, essential for disease management and control. The development of real-time PCR (qPCR) and digital PCR (dPCR) has enhanced PCR's accuracy, sensitivity, and quantification capabilities, making it an even more attractive option in infectious disease testing.
The market is divided into five categories based on end use industry: Hospitals & Diagnostic Laboratories, Research Institutes, Point-of-Care Testing Facilities, Academic and Medical Institutions, and Others. Hospitals experience a high volume of patients with infectious diseases, necessitating advanced diagnostic tools to ensure accurate and timely diagnosis. This drives the demand for molecular diagnostics, which are crucial for detecting pathogens at a molecular level with high specificity and sensitivity. The combination of high patient volumes, technological advancements, integration into patient care, research involvement, and regulatory requirements contributes to the substantial market share held by hospitals in the Infectious Diseases Molecular Diagnostics market.
Infectious Diseases Molecular Diagnostics Market- Geographical Insights
The Asia-Pacific region is witnessing significant growth in the Infectious Diseases Molecular Diagnostics market, driven by factors such as the increasing prevalence of infectious diseases, advancements in healthcare infrastructure, and rising awareness about early disease detection. Countries like China, India, Japan, and South Korea are key contributors to this growth, with a surge in demand for rapid diagnostic tests, particularly in the wake of pandemics such as COVID-19. Additionally, supportive government policies, increased funding for healthcare innovation, and a growing focus on precision medicine are fostering the adoption of molecular diagnostics across the region.
The Infectious Diseases Molecular Diagnostics market is characterized by a competitive landscape featuring key global players, including Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Danaher Corporation, and Hologic Inc. These companies dominate the market due to their strong portfolios of molecular diagnostic platforms, extensive distribution networks, and focus on research and development. Roche, for instance, leads with its highly advanced polymerase chain reaction (PCR) technology. Abbott and Thermo Fisher also hold significant market shares with their offerings in rapid testing and next-generation sequencing (NGS). Mid-sized players like bioMerieux, Qiagen, and Cepheid (a subsidiary of Danaher) are also prominent, providing specialized molecular diagnostic solutions for infectious diseases. Start-ups and regional companies are innovating in niche areas, adding competitive pressure with cost-effective and rapid diagnostic tools. Collaboration and strategic acquisitions are key trends as companies aim to strengthen their portfolios and global reach.
In Jan 2024, Seegene Announced the collaboration with Microsoft to Realize 'a World Free from All Diseases'. This strategic collaboration opens a new chapter in the field of molecular diagnostics that aspires to a world free from all diseases and future pandemics.
In February 2020, Cepheid and Sherlock Biosciences established collaboration on New GeneXpert tests for infectious diseases and oncology leveraging CRISPR Technology. The collaboration will focus on molecular diagnostic tests for infectious diseases and oncology, beginning with a proof-of-concept project focused on the detection of coronavirus (SARS-CoV-2).